

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO,



Publication number: **0 641 566 A1**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : **94306252.1**

(51) Int. Cl.⁶ : **A61K 31/71, A61K 31/365, A61K 31/34**

(22) Date of filing : **24.08.94**

(30) Priority : **25.08.93 US 111796**

(43) Date of publication of application :
08.03.95 Bulletin 95/10

(84) Designated Contracting States :
AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE


(71) Applicant : **ELI LILLY AND COMPANY**
Lilly Corporate Center
Indianapolis Indiana 46285 (US)

(72) Inventor : **Dodge, Jeffrey Alan**
11134 Indian Lake Boulevard
Indianapolis, Indiana 46236 (US)
Inventor : **Sato, Masahiko**
96 Hawthorne Drive
Carmel, Indiana 46033 (US)


(74) Representative : **Hudson, Christopher Mark et al**
Lilly Industries Limited
European Patent Operations
Erl Wood Manor
Windlesham Surrey GU20 6PH (GB)

(54) **Methods of inhibiting vascular restinosis.**


(57) Wortmannin and certain of its analogs are inhibitors of restenosis. Use of the following compounds





wherein R is hydrogen or acetoxy, and R' is C₁-C₆ alkyl ;



EP 0 641 566 A1



wherein R'' is hydrogen, C₁-C₆ alkyl or



wherein R¹ is hydrogen, methyl, or ethyl ; and R² is hydrogen or methyl ; or a pharmaceutically acceptable salt of any of the above.


Vascular restenosis after percutaneous transluminal coronary angioplasty (PTCA) has been shown to be a tissue response characterized by an early and late phase. The early phase occurring hours to days after PTCA is due to thrombosis with some vasospasms while the late phase appears to be dominated by excessive proliferation and migration of smooth muscle cells. In this disease, the increased cell motility and colonization by smooth muscle cells and macrophages contribute significantly to the pathogenesis of the disease. The excessive proliferation and migration of vascular smooth muscle cells may be the primary mechanism to the reocclusion of coronary arteries following PTCA, atherectomy, laser angioplasty and arterial bypass graft surgery. See "Intimal Proliferation of Smooth Muscle Cells as an Explanation for Recurrent Coronary Artery Stenosis after Percutaneous Transluminal Coronary Angioplasty," Austin *et al.*, *Journal of the American College of Cardiology* 8: 369-375 (Aug. 1985).

Vascular restenosis remains a major long term complication following surgical intervention of blocked arteries by percutaneous transluminal coronary angioplasty (PTCA), atherectomy, laser angioplasty and arterial bypass graft surgery. In about 35% of the patients who undergo PTCA, reocclusion occurs within three to six months after the procedure. The current strategies for treating vascular restenosis include mechanical intervention by devices such as stents or pharmacologic therapies including heparin, low molecular weight heparin, coumarin, aspirin, fish oil, calcium antagonist, steroids, and prostacyclin. These strategies have failed to curb the reocclusion rate and have been ineffective for the treatment and prevention of vascular restenosis. See "Prevention of Restenosis after Percutaneous Transluminal Coronary Angioplasty: The Search for a 'Magic Bullet'," Hermans *et al.*, *American Heart Journal* 122: 171-187 (July 1991).

In the pathogenesis of restenosis excessive cell proliferation and migration occurs as a result of growth factors produced by cellular constituents in the blood and the damaged arterial vessel wall which mediate the proliferation of smooth muscle cells in vascular restenosis.

Agents that inhibit the proliferation and/or migration of smooth muscle are useful in the treatment and prevention of restenosis. The present invention provides for the use of wortmannin and certain analogs as restenosis inhibitors.

The invention provides a method of inhibiting restenosis in a subject comprising administering to said subject a pharmaceutically effective dose of a compound selected from the group of




wherein R is hydrogen or acetoxy, and R' is C₁-C₈ alkyl;

5

10


15



20

25

30



wherein R'' is hydrogen, C₁-C₈ alkyl or

35




wherein R''' is hydrogen or C₁-C₆ alkyl;

40




45

50



55 wherein R¹ is hydrogen, methyl, or ethyl; and R² is hydrogen or methyl; or a pharmaceutically acceptable salt of any of the above.


The current invention concerns the discovery that wortmannin and its analogs are useful in the inhibition of retinosis. The following compounds are encompassed by the invention:



5

10


15



20

25


30



35

40

45



50

55




Table 1:

Wortmannin and Analogs					
Formula Designation	R	R ¹	R ²	R ³	Trivial Name
Ia	acetoxy	NA	NA	NA	wortmannin
Ib	H	NA	NA	NA	11-desacetoxywortmannin
II	NA	NA	NA	NA	Δ 9,11-dehydro-desacetoxywortmannin
IIIa	acetoxy	NA	NA	H	17 α -dihydrowortmannin
IIIb	H	NA	NA	H	11-desacetoxy-17 α -dihydrowortmannin
IVa	NA	H	H	NA	opened A-ring acid of wortmannin
IVb	NA	methyl	H	NA	opened A-ring methyl ester of wortmannin

The biosynthetic production of wortmannin (Ia) is well known in the art and the analogs are synthesized from wortmannin. Typically, wortmannin is produced by the fermentation of any one of a number of previously disclosed microorganisms such as *Talaromyces wortmannii* [Nakanishi, *et al.*, *J. Biol. Chem.*, 267 (4): 2157-2163 (1992)]; and *Penicillium wortmannii*, *Myrothecium roridium*, and *Fusarium oxysporum* [Abbas, *et al.*, *Appl. Environ. Microbiol.*, 54(5): 1267-1274 (1988)]. Following fermentation, wortmannin is extracted and purified via known methods.

Preferably, wortmannin is microbially synthesized and isolated in substantially pure form from a fermentation culture identified as A24603.1.

Culture A24603.1 has been deposited in compliance with the Budapest Treaty, and made part of the stock culture collection of the Midwest Area Northern Regional Research Center, Agricultural Research Service, United States Department of Agriculture, 1815 North University Street, Peoria, Illinois, 61604. The accession number is NRRL 2112 (*Penicillium duclauxii*).

The permanency of the deposit of this culture at the Midwest Area Northern Regional Research Center at Peoria, Illinois, and ready accessibility thereto by the public will be afforded throughout the effective life of the patent in the event the patent is granted. Access to the culture will be available during pendency of the application under 37 C.F.R. §1.14 and 35 U.S.C. §112. All restrictions on the availability to the public of the culture will be irrevocably removed upon granting of the patent.

Wortmannin is produced by culturing the above-referenced A24603.1 strain under submerged aerobic conditions in a suitable culture medium until a recoverable amount of wortmannin is produced. Wortmannin can be recovered using various isolation and purification procedures understood in the art.

The medium used to grow the A24603.1 culture can be any one of a number of media. For economy in production, optimal yield, and ease of product isolation, however, preferred carbon sources in large-scale fermentation are glucose and soluble starch such as corn starch. Maltose, ribose, xylose, fructose, galactose, mannose, mannitol, potato dextrin, methyl oleate, oils such as soybean oil and the like can also be used.

Preferred nitrogen sources are enzyme-hydrolyzed casein and cottonseed flour, although pepsinized milk, digested soybean meal, fish meal, corn steep liquor, yeast extract, acid-hydrolyzed casein, beef extract, and the like can also be used.

Among the nutrient inorganic salts which can be incorporated in the culture media are the customary soluble salts capable of yielding calcium, magnesium, sodium, ammonium, chloride, carbonate, sulfate, nitrate, zinc, and like ions.

Essential trace elements necessary for the growth and development of the organism also should be included in the culture medium. Such trace elements commonly occur as impurities in other constituents of the medium in amounts sufficient to meet the growth requirements on the organism.

For production of substantial quantities of wortmannin, submerged aerobic fermentation in stirred bioreactors is preferred. Small quantities of wortmannin may be obtained by shake-flask culture. Because of the time-lag in production commonly associated with inoculation of large bioreactors with the spore form of the organism, it is preferable to use vegetative inoculum. The vegetative inoculum is prepared by inoculating a small volume of culture medium with the spore form or mycelial fragments of the organism to obtain a fresh, actively growing culture of the organism. The vegetative inoculum medium can be the same as that used for larger fermentations, but other media are also suitable.

Wortmannin is produced by the A24603.1 organism when grown at temperatures between about 23° and 29°C. Optimum temperature for wortmannin production appears to be about 25° C.


As is customary in submerged aerobic culture processes, sterile air is blown into the vessels from the bottom while the medium is stirred with conventional turbine impellers. In general, the aeration rate and agitation rate should be sufficient to maintain a level of dissolved oxygen of at least 45% of air saturation with an internal vessel pressure of about 5 atmospheres.

Following its production, wortmannin can be recovered from the fermentation medium by methods used in the art. The wortmannin produced during fermentation of the A24603.1 organism occurs mainly in the broth.

Typically, wortmannin can be recovered from the biomass by a variety of techniques. A preferred technique involves filtering whole fermentation broth with a ceramic filter. The filtrate is eluted with an organic solvent such as ethyl acetate and concentrated. The concentrate is suspended in alcohol until crystallization occurs and the solution is filtered, washed and dried. For confirmation, the crystalline material is dissolved in an organic solvent and chromatographed on a reverse-phase silica gel absorbent (C₈ or C₁₈). Fractions are eluted in an organic-aqueous buffer such as 60% acetonitrile.

11-Deacetoxywortmannin (formula Ib) also is known in the art as are methods for its preparation. Generally, this compound can be biosynthetically produced by fermenting a culture of *Penicillium funiculosum* Thom [see, e.g., Baggolini, *et al.*, *Exp. Cell Res.*, 169: 408-418 (1987)]; but, preferably, is chemically derived from wortmannin by the method disclosed by Haeflinger, *et al.*, *Helv. Chem. Acta*, 56(8): 2901-2904 (1973).

Similarly, the preparation of Δ⁹,11-dehydro-desacetoxywortmannin (formula II) is known in the art and is described by Haeflinger, *et al.*, *supra*; and the preparation of compounds of formula IV is described by MacMillan, J., *et al.*, *J. Chem. Soc., Perkin I*: 2892-2898 (1972). The preparation of compounds of the formula III may be prepared by methods known in the art, and are exemplified in the preparation examples, herein. When Rⁿ is



the compounds may be prepared in an analogous fashion as to that described in Ott *et al.*, *J. Am Chem. Soc.* 74, p. 1239 (1952).

For therapeutic treatment of the specified indications, a compound of formula I, II, III or IV may be administered as such, or can be compounded and formulated into pharmaceutical compositions in unit dosage form for parenteral, transdermal, rectal, nasal, local intravenous administration, or, preferably, oral administration. Such pharmaceutical compositions are prepared in a manner well known in the art and comprise at least one active compound selected from the group consisting of compounds of formulae I, II, III, and IV associated with a pharmaceutically carrier. The term "active compound", as used throughout this specification, refers to at least one compound selected from compounds of the formulas or pharmaceutically acceptable salts thereof.

The term "effective amount" as used herein, means an amount of a compound of the present invention which is capable of inhibiting, blocking, or reversing the activation, migration, or proliferation of cells. The activity contemplated by the present methods includes both medical therapeutic and/or prophylactic treatment, as appropriate. The specific dose of a compound administered according to this invention to obtain a therapeutic and/or prophylactic effects will, of course, be determined by the particular circumstances surrounding

the case, including, for example, the compound administered, the route of administration, and the condition being treated.

The compounds are effective over a wide dosage range and, for example, dosages per day will normally fall within the range of from 0.001 to 10 mg/kg, more usually in the range of from 0.01 to 1 mg/kg. However, it will be understood that the effective amount administered will be determined by the physician in the light of the relevant circumstances including the condition to be treated, the choice of compound to be administered, and the chosen route of administration, and therefore the above dosage ranges are not intended to limit the scope of the invention in any way.

The term "inhibiting" includes the administration of a compound of the present invention to prevent the onset of the symptoms, alleviating the symptoms, or eliminating the disease, condition or disorder.

In such a composition, the active compound is known as "active ingredient". In making the compositions, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semisolid, or liquid material which acts as a vehicle, excipient of medium for the active ingredient. Thus, the composition can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, emulsions, solutions, syrups, suspensions, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

Some examples of suitable carriers, excipients, and diluents include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate alginates, calcium salicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate, water, and mineral oil. The formulations can additionally include lubricating agents, wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavoring agents. The compositions may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

For oral administration, a compound can be admixed with carriers and diluents, molded into tablets, or enclosed in gelatin capsules. The mixtures can alternatively be dissolved in liquids such as 10% aqueous glucose solution, isotonic saline, sterile water, or the like, and administered intravenously or by injection.

By "pharmaceutically acceptable", it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The local delivery of inhibitory amounts of active compound for the treatment of restinosis can be by a variety of techniques which administer the compound at or near the proliferative site. Examples of local delivery techniques are not intended to be limiting but to be illustrative of the techniques available. Examples include local delivery catheters, site specific carriers, implants, direct injection, or direct applications.

Local delivery by a catheter allows the administration of a pharmaceutical agent directly to the proliferative lesion. Examples of local delivery using a balloon catheter are described in EPO 383 492 A2 and U.S. Patent 4,636,195 (Wolinsky, January 13, 1987).

Local delivery by an implant describes the surgical placement of a matrix that contains the pharmaceutical agent into the proliferative lesion. The implanted matrix releases the pharmaceutical agent by diffusion, chemical reaction, or solvent activators. Lange, *Science* 249: 1527-1533 (September, 1990).

An example of local delivery by an implant is the use of a stent. Stents are designed to mechanically prevent the collapse and reocclusion of the coronary arteries. Incorporating a pharmaceutical agent into the stent delivers the drug directly to the proliferative site. Local delivery by this technique is described in Kohn, *Pharmaceutical Technology* (October, 1990).

Another example is a delivery system in which a polymer that contains the pharmaceutical agent is injected into the lesion in liquid form. The polymer then cures to form the implant *in situ*. This technique is described in PCT WO 90/03768 (Donn, April 19, 1990).

Another example is the delivery of a pharmaceutical agent by polymeric endoluminal sealing. This technique uses a catheter to apply a polymeric implant to the interior surface of the lumen. The pharmaceutical agent incorporated into the biodegradable polymer implant is thereby released at the surgical site. It is described in PCT WO 90/01969 (Schindler, August 23, 1989).

A final example of local delivery by an implant is by direct injection of vesicles or microparticulates into the proliferative site. These microparticulates may be composed of substances such as proteins, lipids, carbohydrates or synthetic polymers. These microparticulates have the pharmaceutical agent incorporated throughout the microparticle or over the microparticle as a coating. Delivery systems incorporating microparticulates are described in Lange, *Science* 249: 1527-1533 (September, 1990) and Mathiowitz, *et al.*, *J. App. Poly. Sci.*, 26:809 (1981).

Local delivery by site specific carriers describes attaching the pharmaceutical agent to a carrier which will direct the drug to the proliferative lesion. Examples of this delivery technique includes the use of carriers such

as a protein ligand or a monoclonal antibody. Lange, *Science* 249: 1527-1533 (September).

Local delivery by direct application includes the use of topical applications. An example of a local delivery by direct application is applying the pharmaceutical agent directly to the arterial bypass graft during the surgical procedure.

- 5 The following formulation examples are illustrative only and are not intended to limit the scope of the invention in any way. The meaning of the term "active ingredient" is as defined above.

Formulation 1

- 10 Hard gelatin capsules are prepared using the following ingredients:

	Quantity (mg/capsule)
Active ingredient	250
Starch, dried	200
Magnesium stearate	10
Total	460 mg

Formulation 2

A tablet is prepared using the ingredients below:

	Quantity (mg/capsule)
Active ingredient	250
Cellulose, microcrystalline	400
Silicon dioxide, fumed	10
Stearic acid	5
Total	665 mg

The components are blended and compressed to form tablets each weighing 665 mg.

Formulation 3

- 40 An aerosol solution is prepared containing the following components:

	Weight
Active ingredient	0.25
Ethanol	25.75
Propellant 22 (Chlorodifluoromethane)	70.00
Total	100.00

50 The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to -30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.

Formulation 4

55 Tablets, each containing 60 mg of active ingredient, are made as follows:

Active ingredient	60 mg
Starch	45 mg
Microcrystalline cellulose	35 mg
Polyvinylpyrrolidone (as 10% solution in water)	4 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	1 mg
Total	150 mg

The active ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. Sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.

Formulation 5

Capsules, each containing 80 mg of active ingredient, are made as follows:

Active ingredient	80 mg
Starch	59 mg
Microcrystalline cellulose	59 mg
Magnesium stearate	2 mg
Total	200 mg

The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.

Formulation 6

Suppositories, each containing 225 mg of active ingredient, are made as follows:

Active ingredient	225 mg
Saturated fatty acid glycerides	2,000 mg
Total	2,225 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.

Formulation 7

Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:

Active ingredient(s)	50 mg
Sodium carboxymethyl cellulose	50 mg
Syrup	1.25 mL
Benzoic acid solution	0.10 mL
Flavor	q.v.
Color	q.v.
Purified water to total	5 mL

The active ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.

Formulation 8

An intravenous formulation may be prepared as follows:

Active ingredient	100 mg
Isotonic saline	1,000 mL

Preparation 1

Fermentation of Culture A24603.1

A. Shake-Flask

The culture A24603.1, either as a lyophilized pellet or as a suspension maintained in liquid nitrogen, is used to inoculate a vegetative medium having the following composition

Vegetative Medium

<u>Ingredient</u>	<u>Amount (g/L)</u>
-------------------	---------------------

Glucose	10.0
Glycerol	10.0
Cottonseed Flour ^a	25.0

Unadjusted pH=6.3; no adjustment

^a PROFLO Flour (Traders Protein, Memphis, TN).

The inoculated vegetative medium was incubated in a 250 mL wide-mouth Erlenmeyer flask at 25° C for about 72 hours on a shaker orbiting in a two-inch (5.08 cm) circle at 250 rpm.

B. Tank Fermentation of Culture A24603.1

In order to provide a larger volume of inoculum, 10 mL of incubated shake-flask medium, prepared as described in Section A, was used to inoculate 400 mL of a second-stage vegetative medium having the same composition as described above. This second-stage medium was incubated in a 2-L wide-mouth Erlenmeyer flask at 25° C for about 23 hours on a shaker orbiting in a two-inch (5.08 cm) circle at 250 rpm.

This second-stage medium (400 mL) was used to inoculate 115 L of sterile production medium having the following composition.

10 Production Medium

	<u>Ingredient</u>	<u>Amount (g/L)</u>
15	Glucose	25.0
	Corn Starch	10.0
20	Lexein	10.0
	Enzyme-hydrolyzed casein	4.0
	Blackstrap molasses	5.0
25	MgSO ₄ (anhydrous)	5.0
	CaCO ₃	2.0
30	Deionized H ₂ O	q.s. to 115 L
	Unadjusted pH = 6.8; no adjustment.	
	Antifoam agent added: SAG 471 ^b (0.2 gm/L).	

- 35 ^a NZ Amine A (Sheffield Chemical Co., Norwich, NY).
 ^b SAG 471 (Union Carbide, Sistersville, WV).

40 The inoculated production medium was allowed to ferment in a 115-L stirred fermentation tank for 4-5 days at a temperature of about 25° C. A dissolved oxygen level of about 45% of air saturation was maintained, as was a low rpm (180-330) in the stirred vessel.

Preparation 245 Isolation and Purification of Wortmannin

50 Fermentation broth from Preparation 1 was filtered through a ceramic filter (Membralox Systems, Illinois Water Treatment, Rockford, IL) to yield 175 L of filtrate containing wortmannin. The pH of the filtrate was adjusted to about 3.9 with 5N HCl. The filtrate was then eluted three times with one-half volumes of ethyl acetate to give a combined volume of 207 L which was concentrated to 6 L *in vacuo*.


 The 6 L of ethyl acetate concentrate was further concentrated *in vacuo* to form a dark brown viscous oil to which 500 mL of methanol was added. The mixture was swirled until the resulting crystallization was complete, filtered, briefly washed with cold methanol and dried *in vacuo* to give 20.4 g of wortmannin.

55 The methanol supernatant was reconcentrated *in vacuo* to form a viscous oil, dissolved in 180 mL of chloroform and applied to a 12 x 20 cm column of Woelm Grade 62 silica in chloroform. 5.0 L of chloroform wash was concentrated *in vacuo* to form a brown oil which was then dissolved in 250 mL of warm methanol. The resulting crystals were collected after 18 hours, via filtration, giving 4.2 g of wortmannin. The crystallization

procedure was repeated on the remaining supernatant, yielding an additional 1.9 g of wortmannin. The identity of wortmannin was confirmed by HPLC.

Preparation 3

17 α -Dihydrowortmannin




To a solution of wortmannin (100 mg) stirring in THF at -78°C was added diisobutylaluminum hydride (0.4 mL of a 1.0 M solution in toluene, 0.4 mmol). After 0.5 h, the reaction was quenched with saturated aqueous NaHCO₃. The mixture was then warmed to room temperature and extracted with CH₂Cl₂. The combined organic extracts were washed with brine and dried (MgSO₄). The crude material was purified by radial chromatography (SiO₂, 4 mm, 9:1 EtOAc/Hexanes) to give 17 α -dihydrowortmannin as an off-white powder.

¹H NMR (300 MHz, CDCl₃) 8.22 (s, 1H), 6.10 (m, 1H), 4.76 (dd, 1H), 3.88 (t, 1H), 3.44 (dd, 1H), 3.20 (s, 3H), 2.95 (1/2 ABq, 1H), 2.75 (m, 1H), 2.62 (1/2 ABq, 1H), 2.52 (m, 1H), 2.10-2.30 (m, 4H), 1.4-1.7 (m), 0.85 (s, 3H), MS FD⁺ 431, IR (Cell, CDCl₃), 1751, 1680 cm⁻¹).

Preparation 4

11-Desacetoxy-17 α -dihydrowortmannin



To a solution of compound Ib (15 mg) (prepared via the method of Haefliger, W.; Hauser, D. *Helv. Chim. Acta*, 56, 2901, (1973)) stirring in THF at -78°C was added diisobutylaluminum hydride (0.1 mL of a 1.0 M solution in toluene). After 1h, the reaction was quenched with saturated aqueous NaHCO₃. The mixture was then warmed to room temperature and extracted with CH₂Cl₂. The combined organic extracts were washed with brine and dried (MgSO₄). The crude material was purified by radial chromatography (SiO₂, 1 mm, 9:1 EtOAc/Hexanes) to give the titled product as a tan powder.

¹H-NMR (300 MHz, CDCl₃) 8.19 (s, 1H), 4.81 (t, 1H), 3.80 (t, 1H), 3.15 (s, 3H), 1.7 (s, 3H), 0.7 (s, 3H). MS FAB⁺ 373.3.

Compounds of the invention were tested for impact on smooth muscle cell chemotaxis using a model AB96

Neuro Probe® 96 well chemotaxis chamber. References citing use of this assay are Falk *et al.*, "A 48 Well Micro Chemotaxis Assembly for Rapid and Accurate Measurement of Leukocyte Migration", *J. of Immunological Methods*, 33, pp 239-247 (1980); Harvath *et al.*, "Rapid Quantification of Neutrophil Chemotaxis", *J. of Immunological Methods*, 37, pp 39-45 (1980); Richards *et al.*, "A Modified Microchamber Method for Chemotaxis and Chemokinesis", *Immunological Comm.* 13 (1), pp 49-62 (1984); Harvath *et al.*, "Two Neutrophil Populations in Human Blood with Different Chemotactic Activities", *Inf. and Immunity*, 36(2), pp. 443-449 (1982). This chamber is available from Neuro Probe, Inc., P.O. Box 400, Cabin John, MD 20818.

The chamber consists of a top plate, a bottom plate, a gasket and a polyvinyl pyrrolidone-free polycarbonate filter. The 96 lower plate wells are filled with ~ 30 μ l of media (for control) or PDGF-BB at 10 ng/ml as an inducer, or chemoattractant. The 8 μ m pore filter is soaked in 0.5 N acetic acid overnight and coated with collagen at 100 μ g/ml in 0.1N acetic acid for 2 days. The filter is then dried in a hood. The filter is then installed on the bottom plate, followed by the gasket. The top plate is then placed on the gasket, forming the top wells. In the top wells, smooth muscle cells are placed with the compounds to be tested at specified concentrations in around 225 μ l volume. The smooth muscle cells are plated at a density of 0.5×10^6 cells/ml. The chamber is incubated at 37°C, 5% CO₂ for four hours, and at the end of this time the upper well-cells are scraped off. The lower well cells are fixed, stained, and the absorbance is read. The results are in Table 2.


Based on these assays, the half maximal inhibiting concentrations (IC₅₀) to inhibit smooth muscle cell chemotaxis are: IIIA, IC₅₀=0.02 μ M; Wortmannin, IC₅₀= 0.03 μ M; Ib IC₅₀= 0.2 μ M; II IC₅₀ = 0.2 μ M; IVb, IC₅₀= 10 μ M; and IVA, IC₅₀> 10 μ M.

Table 2



Compound		Degree of Cell Migration
Blank		0.000
PDGF, 10ng/ml		0.046
Colchicine, 1 μ m		0.000
Ia, Wortmannin	0.3 μ m	-0.001
	0.1 μ m	0.006
	0.03 μ m	0.020
Ib	1 μ m	-0.010
	0.3 μ m	0.015
	0.1 μ m	0.040
	0.03 μ m	0.044
II	1 μ m	0.000
	0.3 μ m	0.015
	0.1 μ m	0.028
	0.03 μ m	0.036
IIIA	0.03 μ m	-0.010
	0.1 μ m	-0.010
	0.03 μ m	0.002
	0.01 μ m	0.033
IVA	10 μ m	0.04
IVB	10 μ m	0.026

Claims

1. A compound selected from the group:




20 wherein R is hydrogen or acetoxy, and R' is C₁-C₆ alkyl;



55 wherein R'' is hydrogen, C₁-C₆ alkyl or





wherein R''' is hydrogen or C₁-C₈ alkyl;



20 wherein R¹ is hydrogen, methyl, or ethyl; and R² is hydrogen or methyl; or a pharmaceutically acceptable salt of any of the above; for use in the treatment of restenosis.

2. The use of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating restenosis.


3. The use of a compound according to Claim 1 wherein the compound is selected from



5

10


15



20

25


30



35



40

45



50

55



or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating restenosis.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 94 30 6252

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claims	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	PATENT ABSTRACTS OF JAPAN vol. 15, no. 496 (C-894)(5024) 16 December 1991 & JP-A-03 215 423 (KYOWA) 20 September 1991 * abstract *	1-3	A61K31/71 A61K31/365 A61K31/34
Y	---	2,3	
X	US-A-3 668 222 (HAUSER) 6 June 1972 * see column 3, lines 9-32 *	1	
Y	FEBS vol. 291, no. 2, October 1991 pages 363 - 366 M. KOCHER ET AL. 'Effects of 17-hydroxywortmannin on serine/threonine protein kinases in human blood platelets' * see the abstract *	2,3	
Y	J AM COLL CARDIOL vol. 17, no. 6, May 1991 pages 718 - 768 D.G. HARRISON 'Endothelial modulation of vascular tone: relevance to coronary angioplasty and restenosis' * see the abstract *	2,3	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61K
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 13 December 1994	Examiner Isert, B
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 01.92 (P04C01)